MHCI (H2KB and H2DB), MHCII, CD80, CD86 and PD-L1 expression on the AT3OVA tumours were all significantly increased in response to combined inhibitor treatment compared with vehicle controls (Fig. 2f and Supplementary Fig. 3d). Here, CD86 is linked to neoplasm.